{
    "clinical_study": {
        "@rank": "168010", 
        "acronym": "ERIC", 
        "arm_group": [
            {
                "arm_group_label": "imipenem-treated patients", 
                "description": "imipenem-treated patients"
            }, 
            {
                "arm_group_label": "ertapenem-treated patients", 
                "description": "ertapenem-treated patients"
            }
        ], 
        "biospec_descr": {
            "textblock": "faeces, bacterial DNA"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The use of carbapenems, very broad spectrum antibiotics of last resort, is becoming more\n      common due to the increased prevalence in the hospital and community of extended spectrum\n      \u03b2-lactamase (ESBL) producing gram-negative bacilli (GNB), including CTX-M type, which are\n      resistant to all other \u03b2-lactam antibiotics. Meanwhile, it creates a selective pressure\n      towards emergence of strains which are also resistant to carbapenems, placing patients in a\n      catastrophic situation of therapeutic dead-end. A better understanding of the mechanisms of\n      emergence of BGN resistant to carbapenems is necessary to optimize their use and undertake\n      preventive measures to preserve their effectiveness. The aim of the study is to evaluate and\n      describe the emergence of carbapenem-induced resistant GNB in patient intestinal microflora."
        }, 
        "brief_title": "Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Carbapenem-induced Resistance", 
        "detailed_description": {
            "textblock": "The use of carbapenems, very broad spectrum antibiotics of last resort, is becoming more\n      common due to the increased prevalence in the hospital and community of extended spectrum\n      \u03b2-lactamase (ESBL) producing gram-negative bacilli (GNB), including CTX-M type, which are\n      resistant to all other \u03b2-lactam antibiotics. Meanwhile, it creates a selective pressure\n      towards emergence of strains which are also resistant to carbapenems, placing patients in a\n      catastrophic situation of therapeutic dead-end. A better understanding of the mechanisms of\n      emergence of BGN resistant to carbapenems is necessary to optimize their use and undertake\n      preventive measures to preserve their effectiveness.\n\n      Hypotheses: Carbapenems induce in treated patients the emergence of resistant GNB in\n      intestinal flora and have an impact on colonization resistance of the gut microbiota.\n\n      Primary objective: To determine the frequency of emergence of carbapenems resistant GNB in\n      the intestinal flora at the end of a treatment by imipenem or ertapenem.\n\n      Secondary objective(s):\n\n        -  Assess the presence of carbapenem resistant GNB in the intestinal flora before\n           treatment.\n\n        -  Evaluate the presence and / or persistence of carbapenem resistant GNB in the\n           intestinal flora on day 3 of treatment, and 15 days and 1 month after the end of\n           treatment.\n\n        -  Determine the molecular mechanisms of resistance of strains of interest.\n\n        -  Describe the gastrointestinal tract colonization by non-commensal microorganisms before\n           and after treatment (impact on colonization resistance).\n\n        -  Describe the characteristics of patients with emergence of resistance compared to\n           patients who do not.\n\n        -  Proper conservation of stool of 10 patients for metagenomic and/or metatranscriptomic\n           analysis of changes in the intestinal flora.\n\n      Primary endpoint: Presence of carbapenem resistant GNB in the stool at the end of treatment\n      in patients who did not before, after culture on selective media.\n\n      Secondary endpoints:\n\n        -  Presence of carbapenem resistant GNB in stools before treatment, at day 3 and 15 days\n           and 1 month after stopping treatment, after culture on selective media.\n\n        -  PCR and sequencing of resistance genes from strains of interest.\n\n        -  Colonization of the digestive tract by non-commensal microorganisms before and after\n           treatment.\n\n        -  Characteristics of patients with or without emergence of resistance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age> or = 18 years old\n\n          -  hospitalized\n\n          -  initiating a treatment by imipenem or ertapenem-\n\n          -  faeces harvested before the beginning of treatment\n\n          -  written informed consent from the patient or from a relative if the patient is\n             incapable of expressing his/her consent\n\n          -  reachable by phone after hospitalization (only for patients able to express their\n             consent).\n\n        Exclusion Criteria :\n\n          -  hospitalized in intensive care unit\n\n          -  concomitant antibiotic treatment (except aminosid or vancomycin for less than 4\n             days).\n\n        Secondary exclusion criteria :\n\n          -  introduction of other antibiotics during carbapenem treatment (except vancomycin or\n             aminosid)\n\n          -  vancomycin treatment for more than 4 days during carbapenem treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "hospitalized patients initiating a carbapenem treatment"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703299", 
            "org_study_id": "CRC11016"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Imipenem", 
                "Ertapenem"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "imipenem", 
            "ertapenem", 
            "resistance", 
            "commensal flora"
        ], 
        "lastchanged_date": "December 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92110"
                    }, 
                    "name": "H\u00f4pital Beaujon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colombes", 
                        "country": "France", 
                        "zip": "92700"
                    }, 
                    "name": "H\u00f4pital Louis Mourier"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75018"
                    }, 
                    "name": "H\u00f4pital Bichat-Claude Bernard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint-Louis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }, 
                    "name": "H\u00f4pital Paul Brousse"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments", 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Antoine Andremont, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "faecal bacterial growth on selective culture media", 
            "measure": "presence of carbapenem-resistant gram-negative bacteria at the end of carbapenem treatment in faeces of patients who were free of carbapenem-resistant gram-negative bacteria before the beginning of treatment", 
            "safety_issue": "No", 
            "time_frame": "at the end of carbapenem treatment period which usually lasts between 2 and 15 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "faecal bacterial growth on selective culture media", 
            "measure": "presence of carbapenem-resistant gram-negative bacteria in patient faeces before carbapenem treatment, at day 3 of carbapenem treatment and at day 15 et day 30 after the end of carbapenem treatment", 
            "safety_issue": "No", 
            "time_frame": "before, at day 3 of carbapenem treatment and at day 15 and day 30 after the end of carbapenem treatment"
        }, 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}